References
- Antoniadou A, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 2003;82:309–321.
- Slavin MA, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010:65:1042–1051.
- Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133–163.
- Chen S, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006;12:1508–1516.
- Sipsas NV, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007). Cancer 2009;115:4745–4752.
- Fraser VJ, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15: 414–421.
- Marr KA, et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309–316.
- Bodey GP, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380–385.
- Malani A, et al. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005;41:975–981.
- Andes DR, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012;54:1110–1122.
- Eschenauer GA, et al. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. J Antimicrob Chemother 2013;68:922–926.
- Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
- Henry KW, et al. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Antimicrob Agents Chemother 1999;43:1968–1974.
- Ben-Ami R, Giladi M. Fluconazole-resistant Candida: collateral damage associated with prior antibacterial exposure? Future Microbiol 2012;7:1029–1031.
- Reboli AC, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472–2482.